Modality
Radioligand
MOA
SHP2i
Target
HER2
Pathway
PI3K/AKT
Prostate CaCeliac
Development Pipeline
Preclinical
~Aug 2021
→ ~Nov 2022
Phase 1
Feb 2023
→ Apr 2027
Phase 1Current
NCT06055464
252 pts·Celiac
2023-02→2027-04·Not yet recruiting
252 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-04-061.0y awayInterim· Celiac
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1
Not yet…
Catalysts
Interim
2027-04-06 · 1.0y away
Celiac
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06055464 | Phase 1 | Celiac | Not yet recr... | 252 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| Doxacagene | Sanofi | Approved | PSMA | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Daratuximab | BioMarin | Phase 1 | PRMT5 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα | |
| Talatapinarof | Samsung Biologics | Phase 1/2 | PCSK9 |